361 related articles for article (PubMed ID: 30135091)
1. Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis.
Acosta N; Heirali A; Somayaji R; Surette MG; Workentine ML; Sibley CD; Rabin HR; Parkins MD
Thorax; 2018 Nov; 73(11):1016-1025. PubMed ID: 30135091
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Cystic Fibrosis Microbiome: A Comparative Cohort Study Spanning 16 Years.
Acosta N; Whelan FJ; Somayaji R; Poonja A; Surette MG; Rabin HR; Parkins MD
Ann Am Thorac Soc; 2017 Aug; 14(8):1288-1297. PubMed ID: 28541746
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections.
Heirali A; McKeon S; Purighalla S; Storey DG; Rossi L; Costilhes G; Drews SJ; Rabin HR; Surette MG; Parkins MD
PLoS One; 2016; 11(2):e0148534. PubMed ID: 26859493
[TBL] [Abstract][Full Text] [Related]
4. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.
Zemanick ET; Wagner BD; Robertson CE; Stevens MJ; Szefler SJ; Accurso FJ; Sagel SD; Harris JK
Ann Am Thorac Soc; 2015 Feb; 12(2):221-9. PubMed ID: 25474078
[TBL] [Abstract][Full Text] [Related]
5. Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis.
Syed SA; Whelan FJ; Waddell B; Rabin HR; Parkins MD; Surette MG
Ann Am Thorac Soc; 2016 Dec; 13(12):2132-2142. PubMed ID: 27925791
[TBL] [Abstract][Full Text] [Related]
6. Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum.
Hahn A; Sanyal A; Perez GF; Colberg-Poley AM; Campos J; Rose MC; Pérez-Losada M
J Microbiol Methods; 2016 Nov; 130():95-99. PubMed ID: 27609714
[TBL] [Abstract][Full Text] [Related]
7. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis.
Boutin S; Graeber SY; Weitnauer M; Panitz J; Stahl M; Clausznitzer D; Kaderali L; Einarsson G; Tunney MM; Elborn JS; Mall MA; Dalpke AH
PLoS One; 2015; 10(1):e0116029. PubMed ID: 25629612
[TBL] [Abstract][Full Text] [Related]
8. Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline.
Bacci G; Paganin P; Lopez L; Vanni C; Dalmastri C; Cantale C; Daddiego L; Perrotta G; Dolce D; Morelli P; Tuccio V; De Alessandri A; Fiscarelli EV; Taccetti G; Lucidi V; Bevivino A; Mengoni A
PLoS One; 2016; 11(6):e0156807. PubMed ID: 27355625
[TBL] [Abstract][Full Text] [Related]
9. The metabolic footprint of the airway bacterial community in cystic fibrosis.
Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
[TBL] [Abstract][Full Text] [Related]
10. Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability.
Hampton TH; Thomas D; van der Gast C; O'Toole GA; Stanton BA
Microbiol Spectr; 2021 Sep; 9(1):e0002921. PubMed ID: 34232099
[TBL] [Abstract][Full Text] [Related]
11. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
[TBL] [Abstract][Full Text] [Related]
12. Azithromycin and the microbiota of cystic fibrosis sputum.
Acosta N; Thornton CS; Surette MG; Somayaji R; Rossi L; Rabin HR; Parkins MD
BMC Microbiol; 2021 Mar; 21(1):96. PubMed ID: 33784986
[TBL] [Abstract][Full Text] [Related]
13. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
[TBL] [Abstract][Full Text] [Related]
14. Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function.
Paganin P; Fiscarelli EV; Tuccio V; Chiancianesi M; Bacci G; Morelli P; Dolce D; Dalmastri C; De Alessandri A; Lucidi V; Taccetti G; Mengoni A; Bevivino A
PLoS One; 2015; 10(4):e0124348. PubMed ID: 25898134
[TBL] [Abstract][Full Text] [Related]
15. Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.
Flight WG; Smith A; Paisey C; Marchesi JR; Bull MJ; Norville PJ; Mutton KJ; Webb AK; Bright-Thomas RJ; Jones AM; Mahenthiralingam E
J Clin Microbiol; 2015 Jul; 53(7):2022-9. PubMed ID: 25878338
[TBL] [Abstract][Full Text] [Related]
16. Loss of Microbial Niche Specificity Between the Upper and Lower Airways in Patients With Cystic Fibrosis.
Pletcher SD; Goldberg AN; Cope EK
Laryngoscope; 2019 Mar; 129(3):544-550. PubMed ID: 30284279
[TBL] [Abstract][Full Text] [Related]
17. Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis.
Fenn D; Abdel-Aziz MI; Brinkman P; Kos R; Neerincx AH; Altenburg J; Weersink E; Haarman EG; Terheggen-Lagro SWJ; Maitland-van der Zee AH; Bos LDJ;
J Cyst Fibros; 2022 Jan; 21(1):52-60. PubMed ID: 34548223
[TBL] [Abstract][Full Text] [Related]
18. Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details.
Feigelman R; Kahlert CR; Baty F; Rassouli F; Kleiner RL; Kohler P; Brutsche MH; von Mering C
Microbiome; 2017 Feb; 5(1):20. PubMed ID: 28187782
[TBL] [Abstract][Full Text] [Related]
19. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis.
Armbruster CR; Li K; Kiedrowski MR; Zemke AC; Melvin JA; Moore J; Atteih S; Fitch AC; DuPont M; Manko CD; Weaver ML; Gaston JR; Alcorn JF; Morris A; Methé BA; Lee SE; Bomberger JM
Microbiol Spectr; 2022 Oct; 10(5):e0125122. PubMed ID: 36094193
[TBL] [Abstract][Full Text] [Related]
20. Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: Experience from the OligoG phase 2b clinical trials.
Weiser R; Rye PD; Mahenthiralingam E
J Microbiol Methods; 2021 Feb; 181():106133. PubMed ID: 33421446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
